Affiliations: [a] Laboratory of Teratology and Experimental Oncology, Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot | [b] Institute of Biochemistry, Faculty of Agriculture, Hebrew University of Jerusalem, Rehovot | [c] Department of Clinical Biochemistry, Rambam Medical Center, Haifa | [d] Unit of Gastroenterology, Kaplan Hospital, Rehovot | [e] Institute of Oncology, Kaplan Hospital, Rehovot | [f] Department of Surgery, Kaplan Hospital, Rehovot | [g] Department of Pathology, Kaplan Hospital, Rehovot | [h] Department of Laboratories, Laniado Hospital, Netania, Israel
Abstract: The role of serum levels of p53 antigen in detection of colon cancer was studied in different groups of cancer and noncancer patients and was compared with the results of immunohistochemical analyses. The p53 antigen was isolated from the human serum as a cytoplasmic fraction using the recently described new type of columns for affinity chromatography, gel fiberglass columns (Zusman and Zusman, 1995). Its concentration was detected by high performance liquid chromatography. The serum level of the p53 antigen significantly increased in cancer patients (3.6 mg ml−1) as compared to its concentration in patients with benign tumors (1.7 mg ml−1) or in patients with noncancer disorders (0.49 mg ml−1), and this was found to be a result of higher concentration of p53,protein in tumor cells. Coefficient of correlation between cellular concentration of p53 protein and its serum level was 0.44 in noncancer lesions and 0.48 in cancer patients. Serum levels of p53 antigen was shown to be highly active either in patients with noncancer lesions or in patients with cancer (r = 0.46 and 0.51 respectively), whereas the cell determination of p53 protein was effective only among noncancer patients (r = 0.61) but not in cancer patients (r = 0.22). The finding suggests that serum determination of p53 antigen can perhaps reveal this oncoprotein already in the early stages of cancer or even predict the putative development of cancer. The possibility to use the serum-levels of p53 antigen in the follow up patients with chronic diseases and to detect transformation of these diseases into cancer, or monitoring former cancer patients in order to detect as early as possible the incidence of recurrent cancer is discussed.
